1,064 reports of this reaction
6.3% of all ROCURONIUM BROMIDE reports
#2 most reported adverse reaction
HYPOTENSION is the #2 most commonly reported adverse reaction for ROCURONIUM BROMIDE, manufactured by Fresenius Kabi USA, LLC. There are 1,064 FDA adverse event reports linking ROCURONIUM BROMIDE to HYPOTENSION. This represents approximately 6.3% of all 16,854 adverse event reports for this drug.
Patients taking ROCURONIUM BROMIDE who experience hypotension should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HYPOTENSION is moderately reported among ROCURONIUM BROMIDE users, representing a notable but not dominant share of adverse events.
In addition to hypotension, the following adverse reactions have been reported for ROCURONIUM BROMIDE:
The following drugs have also been linked to hypotension in FDA adverse event reports:
HYPOTENSION has been reported as an adverse event in 1,064 FDA reports for ROCURONIUM BROMIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
HYPOTENSION accounts for approximately 6.3% of all adverse event reports for ROCURONIUM BROMIDE, making it one of the most commonly reported side effect.
If you experience hypotension while taking ROCURONIUM BROMIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.